AU2006254809B2 - Indane derivatives as modulators of ion channels - Google Patents

Indane derivatives as modulators of ion channels Download PDF

Info

Publication number
AU2006254809B2
AU2006254809B2 AU2006254809A AU2006254809A AU2006254809B2 AU 2006254809 B2 AU2006254809 B2 AU 2006254809B2 AU 2006254809 A AU2006254809 A AU 2006254809A AU 2006254809 A AU2006254809 A AU 2006254809A AU 2006254809 B2 AU2006254809 B2 AU 2006254809B2
Authority
AU
Australia
Prior art keywords
optionally substituted
pain
ring
compound according
aliphatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006254809A
Other languages
English (en)
Other versions
AU2006254809A1 (en
Inventor
Aarti S. Kawatkar
Esther Martinborough
Timothy Neubert
Andreas Termin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of AU2006254809A1 publication Critical patent/AU2006254809A1/en
Application granted granted Critical
Publication of AU2006254809B2 publication Critical patent/AU2006254809B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/47—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2006254809A 2005-06-09 2006-06-09 Indane derivatives as modulators of ion channels Ceased AU2006254809B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68891905P 2005-06-09 2005-06-09
US60/688,919 2005-06-09
PCT/US2006/022818 WO2006133459A1 (en) 2005-06-09 2006-06-09 Indane derivatives as modulators of ion channels

Publications (2)

Publication Number Publication Date
AU2006254809A1 AU2006254809A1 (en) 2006-12-14
AU2006254809B2 true AU2006254809B2 (en) 2012-03-15

Family

ID=37000013

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006254809A Ceased AU2006254809B2 (en) 2005-06-09 2006-06-09 Indane derivatives as modulators of ion channels

Country Status (14)

Country Link
US (2) US7605174B2 (enExample)
EP (1) EP1888547A1 (enExample)
JP (2) JP2008543785A (enExample)
KR (1) KR20080019693A (enExample)
CN (1) CN101238109B (enExample)
AU (1) AU2006254809B2 (enExample)
CA (1) CA2611731A1 (enExample)
IL (1) IL187997A0 (enExample)
MX (1) MX2007015726A (enExample)
NO (1) NO20080141L (enExample)
NZ (1) NZ564374A (enExample)
RU (1) RU2007148504A (enExample)
WO (1) WO2006133459A1 (enExample)
ZA (1) ZA200800191B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7615563B2 (en) * 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
US7786137B2 (en) 2005-05-10 2010-08-31 Vertex Pharmaceuticals Incorporated Bicyclic derivatives as modulators of ion channels
KR20080021030A (ko) * 2005-05-16 2008-03-06 버텍스 파마슈티칼스 인코포레이티드 이온 채널 조절인자로서의 바이사이클릭 유도체
WO2007030618A2 (en) * 2005-09-09 2007-03-15 Vertex Pharmaceuticals Incorporated Bicyclic derivatives as modulators of voltage gated ion channels
BRPI0616872A2 (pt) 2005-10-06 2011-07-05 Sanofi Aventis [1,3,4]-tiadiazol-2il-amidas de ácido aril-sulfÈnico bicìclico, produto farmacêutico compreendendo os mesmos, uso e processo para a preparação do referido produto farmacêutico
EP1948597A1 (en) * 2005-10-21 2008-07-30 Vertex Pharmaceuticals Incorporated Derivatives for modulation of ion channels
NZ593074A (en) 2005-12-21 2012-04-27 Vertex Pharma sulfonamide-pyrrolidone derivatives as Modulators of Ion Channels
NZ581309A (en) 2007-05-25 2012-02-24 Vertex Pharma Ion channel modulators and methods of use
US7994174B2 (en) * 2007-09-19 2011-08-09 Vertex Pharmaceuticals Incorporated Pyridyl sulfonamides as modulators of ion channels
AU2008321142A1 (en) * 2007-11-13 2009-05-22 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
AU2008321137A1 (en) 2007-11-13 2009-05-22 Vertex Pharmaceuticals Incorporated 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl)benzenesulfonamide derivati ves and related compounds as modulators of ion channels for the treatment of pain
WO2009133641A1 (ja) * 2008-04-30 2009-11-05 シャープ株式会社 照明装置、及び表示装置
CN102099356A (zh) * 2008-07-01 2011-06-15 沃泰克斯药物股份有限公司 用作离子通道调节剂的杂环衍生物
EP2323482A4 (en) * 2008-08-06 2011-08-17 Merck & Co Inc SUBSTITUTED DIHYDROISOCHINOLINONE AND ISOCHINOLINDION DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
MX2014005068A (es) * 2011-10-28 2014-07-30 Merck Sharp & Dohme Compuestos de benzoxazolinona con actividad selectiva en canales de sodio activados por voltaje.
WO2014061970A1 (en) 2012-10-15 2014-04-24 Daewoong Pharmaceutical Co., Ltd. Sodium channel blockers, preparation method thereof and use thereof
ES2857687T3 (es) 2013-01-31 2021-09-29 Vertex Pharma Piridona amidas como moduladores de los canales de sodio
JP7042256B2 (ja) * 2016-05-19 2022-03-25 タブラ・ラサ・ヘルスケア，インコーポレーテッド 薬剤関連毒性が低減した治療法および処方薬に起因する患者危害の可能性を確認する方法
AU2019301628C1 (en) 2018-07-09 2025-02-06 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting NaV1.8
SG11202100137TA (en) 2018-07-09 2021-02-25 Lieber Institute Inc PYRIDAZINE COMPOUNDS FOR INHIBITING Nav1.8
CN112996776B (zh) * 2019-02-20 2024-03-15 福建盛迪医药有限公司 6-氧代-1,6-二氢哒嗪类前药衍生物、其制备方法及其在医药上的应用
CR20230576A (es) 2021-06-14 2024-04-05 Scorpion Therapeutics Inc Derivados de la urea que pueden ser utilizados para tratar el cáncer
CN116041230B (zh) * 2023-01-08 2024-03-19 中国海洋大学 一种nlrp3炎症小体抑制剂及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005013914A2 (en) * 2003-08-08 2005-02-17 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
GB9800750D0 (en) * 1998-01-14 1998-03-11 Lilly Co Eli Pharmaceutical compound
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005013914A2 (en) * 2003-08-08 2005-02-17 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain

Also Published As

Publication number Publication date
EP1888547A1 (en) 2008-02-20
WO2006133459A1 (en) 2006-12-14
JP2012126745A (ja) 2012-07-05
RU2007148504A (ru) 2009-06-27
IL187997A0 (en) 2008-03-20
NO20080141L (no) 2008-01-09
MX2007015726A (es) 2008-03-04
US7989481B2 (en) 2011-08-02
NZ564374A (en) 2010-11-26
CN101238109A (zh) 2008-08-06
JP2008543785A (ja) 2008-12-04
CA2611731A1 (en) 2006-12-14
US7605174B2 (en) 2009-10-20
US20070117801A1 (en) 2007-05-24
KR20080019693A (ko) 2008-03-04
CN101238109B (zh) 2011-12-14
ZA200800191B (en) 2009-04-29
AU2006254809A1 (en) 2006-12-14
HK1119433A1 (en) 2009-03-06
US20090326023A1 (en) 2009-12-31

Similar Documents

Publication Publication Date Title
US7989481B2 (en) Indane derivatives as modulators of ion channels
US8536195B2 (en) Bicyclic derivatives as modulators of ion channels
EP1891063B1 (en) Bicyclic derivatives as modulators of ion channels
US8492403B2 (en) Bicyclic derivatives as modulators of voltage gated ion channels
AU2006304283B2 (en) Biphenyl derivatives as modulators of voltage gated ion channels

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired